Regulation - Sanofi, Oncology

Filter

Current filters:

SanofiOncology

Popular Filters

NICE final guidance again rejects Sanofi’s Zaltrap for colorectal cancer

25-03-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE), today issued final guidance…

Northern EuropeOncologyPharmaceuticalPricingRegulationSanofiUKZaltrap

Brazil Court annuls marketing approval for sub-standard Taxotere biosimilar

Brazil Court annuls marketing approval for sub-standard Taxotere biosimilar

28-11-2013

The Superior Court of Justice in Brazil recently annulled marketing approval for a sub-standard biosimilar…

BiosimilarsDoxelibGenericsLegalLibra LaboratoryOncologyRegulationSanofiSouth AmericaTaxotere

Following talks with FDA, Sanofi drops fedratinib development

Following talks with FDA, Sanofi drops fedratinib development

18-11-2013

French drug major Sanofi this morning revealed its decision to halt all clinical trials and cancel plans…

fedratinibOncologyPharmaceuticalRegulationResearchSanofi

UK's NICE issues negative new draft guidance on Sanofi's Zaltrap

21-06-2013

The UK's drug watchdog the National Institute for Health Care and Excellence (NICE) has issued new draft…

EuropeOncologyPharmaceuticalPricingRegulationSanofiZaltrap

Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results

17-05-2013

French drug major Sanofi (Euronext: SAN) and NYSE: SNY) this morning (May 17) revealed that the pivotal…

OncologyPharmaceuticalRegulationResearchSanofiSAR302503

Sanofi's Zaltrap gets EU approval for metastatic colorectal cancer

06-02-2013

In a second European approval within a matter of days, French drug major Sanofi (Euronext: SAN) said…

EuropeOncologyPharmaceuticalRegeneronRegulationSanofiZaltrap

Positive CHMP recommendations for Sanofi and Novartis, but not for Celgene

19-11-2012

There was a batch of good news for two pharma companies and a negative opinion for one last Friday coming…

BexseroBiotechnologyCelgeneDiabetesEuropeIstodaxLyxumiaNovartisOncologyPharmaceuticalRegulationSanofiVaccinesZaltrap

Bayer's Stivarga races to FDA approval on the heels of Zaltrap

07-10-2012

The earlier than expected US Food and Drug Administration approval of German drug major Bayer's (BAYN:…

BayerBiotechnologyMarkets & MarketingNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationSanofiStivargaZaltrap

Zaltrap gains US approval for metastatic colorectal cancer

06-08-2012

The US Food and Drug Administration on Friday approved French drug major Sanofi (Euronext: SAN) and US…

North AmericaOncologyPharmaceuticalRegeneronRegulationSanofiZaltrap

Batch of mixed opinions from FDA advisory panels

21-06-2012

Advisory panels of the US Food and Drug Administration meeting yesterday came back with a mixture of…

carfilzomibKyprolisMerck & CoNorth AmericaOncologyOnyx PharmaceuticalsPfizerPharmaceuticalPneumovaxPrevnarRegulationSanofisemuloparinVaccines

UK's NICE negative on Sanofi's Jevtana, but backs Botox for migraine

11-05-2012

Confirming previous negative guidance (The Pharma Letter January 12), UK drugs watchdog the National…

AllerganBotoxEuropeJevtanaNeurologicalOncologyPharmaceuticalPricingRegulationSanofi

Some advantages seen for Sanofi’s Jevtana by Germany’s IQWiG

25-01-2012

In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG)…

EuropeJevtanaOncologyPharmaceuticalPricingRegulationSanofi

Negative NICE guidance for Sanofi prostate cancer drug

12-01-2012

The UK’s drug watchdog the National Institute for Health and Clinical Excellence (NICE), has today…

EuropeJevtanaOncologyPharmaceuticalPricingRegulationSanofi

Back to top